175 related articles for article (PubMed ID: 37986208)
21. Integrated, Integral, and Exploratory Biomarkers in the Development of Poly(ADP-Ribose) Polymerase Inhibitors.
Konecny GE; Chander C; Zhang L
Cancer J; 2021 Nov-Dec 01; 27(6):482-490. PubMed ID: 34904811
[TBL] [Abstract][Full Text] [Related]
22. Tumor Mutational Burden Guides Therapy in a Treatment Refractory
Bhangoo MS; Boasberg P; Mehta P; Elvin JA; Ali SM; Wu W; Klempner SJ
Oncologist; 2018 May; 23(5):518-523. PubMed ID: 29386312
[TBL] [Abstract][Full Text] [Related]
23. Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy.
Miller RE
Cancer J; 2021 Nov-Dec 01; 27(6):506-510. PubMed ID: 34904814
[TBL] [Abstract][Full Text] [Related]
24. Current trends in chemotherapy for advanced ovarian cancer.
Takahashi N; Takekuma M
Jpn J Clin Oncol; 2022 Aug; 52(8):806-815. PubMed ID: 35521913
[TBL] [Abstract][Full Text] [Related]
25. Pan-Cancer Analysis of Copy-Number Features Identifies Recurrent Signatures and a Homologous Recombination Deficiency Biomarker to Predict Poly (ADP-Ribose) Polymerase Inhibitor Response.
Moore JA; Chen KT; Madison R; Newberg JY; Fleischmann Z; Wang S; Sharaf R; Murugesan K; Fendler BJ; Hughes J; Schrock AB; Hegde PS; Oxnard GR; Fabrizio D; Frampton GM; Antonarakis ES; Sokol ES; Jin DX
JCO Precis Oncol; 2023 Sep; 7():e2300093. PubMed ID: 37769224
[TBL] [Abstract][Full Text] [Related]
26. Recent Insights into PARP and Immuno-Checkpoint Inhibitors in Epithelial Ovarian Cancer.
Revythis A; Limbu A; Mikropoulos C; Ghose A; Sanchez E; Sheriff M; Boussios S
Int J Environ Res Public Health; 2022 Jul; 19(14):. PubMed ID: 35886427
[TBL] [Abstract][Full Text] [Related]
27. Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective.
Herzog TJ; Vergote I; Gomella LG; Milenkova T; French T; Tonikian R; Poehlein C; Hussain M
Eur J Cancer; 2023 Jan; 179():136-146. PubMed ID: 36563604
[TBL] [Abstract][Full Text] [Related]
28. Genomic-Based Therapy of Gynecologic Malignancies.
Markman M
Acta Med Acad; 2019 Apr; 48(1):84-89. PubMed ID: 31264436
[TBL] [Abstract][Full Text] [Related]
29. Poly(ADP-ribose) polymerase inhibitors in combination with anti-angiogenic agents for the treatment of advanced ovarian cancer.
Le Saux O; Vanacker H; Guermazi F; Carbonnaux M; Roméo C; Larrouquère L; Trédan O; Ray-Coquard I
Future Oncol; 2021 Jun; 17(18):2291-2304. PubMed ID: 33726504
[TBL] [Abstract][Full Text] [Related]
30. The Role of PARP Inhibitors in Patients with Primary Malignant Central Nervous System Tumors.
Gueble SE; Vasquez JC; Bindra RS
Curr Treat Options Oncol; 2022 Nov; 23(11):1566-1589. PubMed ID: 36242713
[TBL] [Abstract][Full Text] [Related]
31. Targeting DNA Repair Response Promotes Immunotherapy in Ovarian Cancer: Rationale and Clinical Application.
Xie H; Wang W; Qi W; Jin W; Xia B
Front Immunol; 2021; 12():661115. PubMed ID: 34712221
[TBL] [Abstract][Full Text] [Related]
32. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
[TBL] [Abstract][Full Text] [Related]
33. U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis.
Dottino JA; Moss HA; Lu KH; Secord AA; Havrilesky LJ
Obstet Gynecol; 2019 Apr; 133(4):795-802. PubMed ID: 30870286
[TBL] [Abstract][Full Text] [Related]
34. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.
Watkins JA; Irshad S; Grigoriadis A; Tutt AN
Breast Cancer Res; 2014 Jun; 16(3):211. PubMed ID: 25093514
[TBL] [Abstract][Full Text] [Related]
35. The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
Lau CH; Seow KM; Chen KH
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897700
[TBL] [Abstract][Full Text] [Related]
36. PARP inhibitors in ovarian cancer: evidence for maintenance and treatment strategies.
Bahena-González A; Toledo-Leyva A; Gallardo-Rincón D
Chin Clin Oncol; 2020 Aug; 9(4):51. PubMed ID: 32819110
[TBL] [Abstract][Full Text] [Related]
37. Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
Sheta R; Bachvarova M; Plante M; Renaud MC; Sebastianelli A; Gregoire J; Navarro JM; Perez RB; Masson JY; Bachvarov D
J Transl Med; 2020 Nov; 18(1):439. PubMed ID: 33213473
[TBL] [Abstract][Full Text] [Related]
38. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations.
Miller RE; Ledermann JA
Clin Adv Hematol Oncol; 2016 Sep; 14(9):704-11. PubMed ID: 27673289
[TBL] [Abstract][Full Text] [Related]
39. Odontogenic Carcinosarcoma: Clinicopathologic and Molecular Features of Three Cases, a Literature Review and Nomenclature Proposal.
Cole G; Chi A; Cook DR; Kubik M; Bilodeau EA; Seethala RR
Head Neck Pathol; 2023 Sep; 17(3):751-767. PubMed ID: 37486533
[TBL] [Abstract][Full Text] [Related]
40. PARP Inhibitors in Epithelial Ovarian Cancer.
Taylor KN; Eskander RN
Recent Pat Anticancer Drug Discov; 2018; 13(2):145-158. PubMed ID: 29205122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
